Shire plc News

Shire plc , the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association 166th Annual Meeting in .

About Court Report Supplement: Periodically, we will report on biotech and pharma cases that were inadvertently omitted from our Court Report column Tawnsaura Group, LLC v. Direct Digital, LLC 8:13-cv-00004; filed January 2, 2013 in the Central District of California Infringement of U.S. Patent Nos.

On 8 May, the biotechnology company Nimbus Discovery announced an agreement with the specialty pharmaceutical developer Shire plc that combines an innovative technology for drug discovery with a novel financing method to move that technology forward.

U.K. stocks climbed for a seventh day, their longest winning streak since July 2011, led by a rally in BT Group Plc after the telecommunications operator reported earnings that beat analyst estimates.

Shares in BT Group soared on Friday after posting very strong results which saw annual pre-tax profit rise 11 per cent.

Shares of Shire Plc. opened at 93.25 on Friday. Shire Plc. has a one year low of $80.09 and a one year high of $102.04. The stock's 50-day moving average is currently $91.00. The company has a market cap of $17.142 billion and a P/E ratio of 30.47. Shire Plc.

Editor's Note: Related tickers: BT Group plc , Shire PLC , Royal Bank of Scotland Group plc , ITV plc , British American Tobacco plc , ArcelorMittal , British Sky Broadcasting Group plc , Lloyds Banking Group PLC , HSBC Holdings plc , Philip Morris International Inc.

The UK market opened with moderate gains on Friday morning, after a breakout - overnight - by the Japanese Yen, in its cross against the US dollar, apparently stoked risk appetite in capital markets globally.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! PHILADELPHIA, May 9, 2013 /PRNewswire/ - Shire plc , announces that its subsidiary, Shire Development LLC, has prevailed in its litigation against Watson Pharmaceuticals Inc., Watson Laboratories, Inc.-Florida, Watson Pharma, Inc.

Drug company Shire PLC said Thursday that it has prevailed in its litigation against Watson companies that are now part of Actavis Inc.

Nimbus Discovery, LLC, a biotechnology company discovering novel medicines against exciting but previously inaccessible disease targets, today announced a co-development agreement with Shire plc focused on small molecule treatments for several rare genetic diseases known as lysosomal storage disorders .

Editor's Note: Related tickers: Credit Suisse Group AG , AngloGold Ashanti Limited , Goldman Sachs Group, Inc.

The firm currently has a buy rating on the stock. SHPGY has been the subject of a number of other recent research reports.

A number of other analysts have also recently weighed in on SHPGY. Analysts at JP Morgan Cazenove reiterated an overweight rating on shares of Shire PLC in a research note to investors on Thursday.

Merieux Developpement led the financing with participation from all current Neurophage investors, including Shire LLC.

Irish drugmaker Shire PLC said Thursday its net income fell in the first quarter, and it lowered its revenue forecast because sales of several of its drugs are under pressure.

's stock had its "outperform" rating reiterated by equities research analysts at Credit Suisse in a research note issued to investors on Friday, Stock Ratings Network reports.

The European Central Bank reduced its main rate by 25 basis points to 0.50 percent, its first cut in 10 months and an all-time low, and kept alive the possibility of further action in an effort to stimulate the euro zone economy.

Stocks returned to flat territory in London on Thursday, losing then regaining ground in the wake of a European Central Bank interest-rate cut and better-than-forecast U.S. data.

's stock had its "buy" rating reaffirmed by Panmure Gordon in a research note issued on Thursday, AnalystRatings.Net reports.